A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer

LESSONS LEARNED: The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy. Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily. The limited anticancer activity observed in this unselected patient...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Kim, Richard, Tan, Elaine, Wang, Emily, Mahipal, Amit, Chen, Dung‐Tsa, Cao, Biwei, Masawi, Fadzai, Machado, Cindy, Yu, James, Kim, Dae Won
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186409/
https://ncbi.nlm.nih.gov/pubmed/32776632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0759
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky